NCT02163915View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG

TAK-137

TAK-137 tablets

DRUG

TAK-137 Placebo

TAK-137 placebo-matching tablets

Trial Locations (1)

08053

Marlton

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02163915 - Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder. | Biotech Hunter | Biotech Hunter